Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of CVS Health Co. (NYSE:CVS – Free Report) during the fourth quarter, HoldingsChannel reports. The firm bought 209,888 shares of the pharmacy operator’s stock, valued at approximately $9,422,000.
A number of other large investors also recently bought and sold shares of the company. Essential Planning LLC. bought a new position in CVS Health during the 4th quarter worth approximately $3,238,000. Hopwood Financial Services Inc. bought a new position in CVS Health during the 4th quarter worth approximately $29,000. EverSource Wealth Advisors LLC lifted its holdings in CVS Health by 3.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 16,318 shares of the pharmacy operator’s stock worth $733,000 after buying an additional 490 shares during the last quarter. Cornerstone Advisors LLC lifted its holdings in CVS Health by 7.7% during the 4th quarter. Cornerstone Advisors LLC now owns 29,300 shares of the pharmacy operator’s stock worth $1,315,000 after buying an additional 2,100 shares during the last quarter. Finally, Pzena Investment Management LLC raised its position in shares of CVS Health by 49.3% during the 4th quarter. Pzena Investment Management LLC now owns 19,610,579 shares of the pharmacy operator’s stock worth $880,319,000 after purchasing an additional 6,475,271 shares during the period. Institutional investors own 80.66% of the company’s stock.
Analysts Set New Price Targets
A number of analysts have recently weighed in on CVS shares. Cantor Fitzgerald upgraded CVS Health from a “neutral” rating to an “overweight” rating in a research report on Wednesday, February 12th. Leerink Partners upgraded CVS Health from a “market perform” rating to an “outperform” rating and increased their price target for the stock from $55.00 to $75.00 in a research report on Thursday, February 13th. Truist Financial increased their price target on CVS Health from $60.00 to $76.00 and gave the stock a “buy” rating in a research report on Thursday, February 13th. Wells Fargo & Company raised their target price on CVS Health from $68.00 to $73.00 and gave the company an “overweight” rating in a research report on Thursday, February 13th. Finally, Argus set a $77.00 target price on CVS Health in a research report on Tuesday, February 18th. Four research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $69.83.
CVS Health Stock Down 0.2 %
Shares of CVS stock opened at $65.63 on Friday. CVS Health Co. has a 1 year low of $43.56 and a 1 year high of $80.75. The stock has a market cap of $82.75 billion, a PE ratio of 17.93, a price-to-earnings-growth ratio of 0.98 and a beta of 0.53. The business’s fifty day moving average is $58.47 and its 200-day moving average is $57.00. The company has a debt-to-equity ratio of 0.80, a quick ratio of 0.60 and a current ratio of 0.81.
CVS Health (NYSE:CVS – Get Free Report) last released its quarterly earnings data on Wednesday, February 12th. The pharmacy operator reported $1.19 earnings per share for the quarter, topping the consensus estimate of $0.89 by $0.30. CVS Health had a return on equity of 9.11% and a net margin of 1.24%. Equities analysts expect that CVS Health Co. will post 5.89 earnings per share for the current fiscal year.
CVS Health Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Monday, February 3rd. Stockholders of record on Thursday, January 23rd were paid a dividend of $0.665 per share. This represents a $2.66 annualized dividend and a dividend yield of 4.05%. The ex-dividend date of this dividend was Thursday, January 23rd. CVS Health’s dividend payout ratio is presently 72.68%.
Insider Transactions at CVS Health
In related news, Director Michael F. Mahoney acquired 30,000 shares of CVS Health stock in a transaction dated Tuesday, February 18th. The stock was acquired at an average cost of $66.70 per share, with a total value of $2,001,000.00. Following the purchase, the director now directly owns 39,356 shares in the company, valued at $2,625,045.20. The trade was a 320.65 % increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP James David Clark sold 7,513 shares of the firm’s stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $66.35, for a total value of $498,487.55. Following the completion of the sale, the senior vice president now directly owns 8,394 shares of the company’s stock, valued at approximately $556,941.90. This trade represents a 47.23 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 0.24% of the company’s stock.
About CVS Health
CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.
Read More
- Five stocks we like better than CVS Health
- Options Trading – Understanding Strike Price
- Rubrik Stock’s V-Bottom Reversal Signals a Major Rally Ahead
- How to Plot Fibonacci Price Inflection Levels
- How Super Micro Computer Stock Is Defying the Market Sell-Off
- Basic Materials Stocks Investing
- AppLovin vs. HPE: Which Tech Stock Can Bounce Back Faster?
Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Co. (NYSE:CVS – Free Report).
Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.